Loading…
Topic
1 post about Antibodies. Every summary links to the original.
See the idea
Antibody discovery is a three-stage prediction pipeline, and AI models that excel on familiar targets degrade sharply on unfamiliar ones. This explainer maps where that gap appears and what it costs.
The Good Stuff
Paid picks we use ourselves. Links carry a referral code — a subscription through one earns us a commission at no extra cost to you.
Newest first
Monoclonal antibodies are a mainstay of biopharmaceutical development, with over 100 FDA-approved drugs and established manufacturing and regulatory pathways, yet conventional discovery is costly and slow, typically taking six to twelve months from target to lead candidate. AI promises to make antibody development cheaper, faster, and more flexible by designing and characterizing therapeutic antibodies computationally, but scientific questions remain. Development hinges on three factors: the best binding site on the target, which candidates bind most tightly, and whether candidates can survive manufacturing and the clinic. Predictive models for each factor do well on familiar targets and assays but considerably worse on unfamiliar ones, a gap that in-distribution benchmarks have made difficult to measure. Three papers from Amazon Bio Discovery’s science team address research questions about each factor, with methods integrated into the AI-powered application that connects biological AI models with lab services.
The best engineering reads, once a week.
